• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌发生与治疗中的DNA修复及损伤途径

DNA repair and damage pathways in breast cancer development and therapy.

作者信息

Majidinia Maryam, Yousefi Bahman

机构信息

Solid Tumor Research Center, Urmia University of Medical Sciences, Urmia, Iran.

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Molecular Targeting Therapy Research Group, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

出版信息

DNA Repair (Amst). 2017 Jun;54:22-29. doi: 10.1016/j.dnarep.2017.03.009. Epub 2017 Apr 21.

DOI:10.1016/j.dnarep.2017.03.009
PMID:28437752
Abstract

DNA damage/repair constitutes several key pathways working in concert to eliminate DNA lesions and maintain genome stability and integrity. Defective components in DNA damage and repair machinery are an underlying cause for the development and progression of different types of cancers, and breast cancer is no exception. In this paper, we will briefly explain the importance of DNA damage and repair, introduce the current classification schemes for breast cancer, and review the known defects in the repair machinery that have been associated with the risk of breast cancer. Finally, we discuss how the understanding of these pathways can help to design therapeutics for specific targeting of breast cancer tumors.

摘要

DNA损伤/修复由几个协同作用的关键途径组成,以消除DNA损伤并维持基因组的稳定性和完整性。DNA损伤和修复机制中的缺陷成分是不同类型癌症发生和发展的根本原因,乳腺癌也不例外。在本文中,我们将简要解释DNA损伤和修复的重要性,介绍目前乳腺癌的分类方案,并综述与乳腺癌风险相关的修复机制中已知的缺陷。最后,我们讨论对这些途径的理解如何有助于设计针对乳腺癌肿瘤的特异性治疗方法。

相似文献

1
DNA repair and damage pathways in breast cancer development and therapy.乳腺癌发生与治疗中的DNA修复及损伤途径
DNA Repair (Amst). 2017 Jun;54:22-29. doi: 10.1016/j.dnarep.2017.03.009. Epub 2017 Apr 21.
2
DNA damage repair functions and targeted treatment in breast cancer.乳腺癌中的 DNA 损伤修复功能与靶向治疗。
Breast Cancer. 2020 May;27(3):355-362. doi: 10.1007/s12282-019-01038-2. Epub 2020 Jan 2.
3
DNA damage repair in breast cancer and its therapeutic implications.乳腺癌中的DNA损伤修复及其治疗意义。
Pathology. 2017 Feb;49(2):156-165. doi: 10.1016/j.pathol.2016.11.002. Epub 2016 Dec 26.
4
DNA damage response and repair in pancreatic cancer development and therapy.DNA 损伤反应和修复在胰腺癌发生和治疗中的作用。
DNA Repair (Amst). 2021 Jul;103:103116. doi: 10.1016/j.dnarep.2021.103116. Epub 2021 Apr 15.
5
Targeting DNA repair in breast cancer: a clinical and translational update.针对乳腺癌的 DNA 修复:临床与转化研究进展。
Cancer Treat Rev. 2010 Nov;36(7):557-65. doi: 10.1016/j.ctrv.2010.03.006. Epub 2010 Apr 10.
6
Defective DNA repair systems and the development of breast and prostate cancer (review).DNA 修复系统缺陷与乳腺癌和前列腺癌的发生(综述)。
Int J Oncol. 2013 Jan;42(1):29-34. doi: 10.3892/ijo.2012.1696. Epub 2012 Nov 14.
7
DNA damage response and repair in colorectal cancer: Defects, regulation and therapeutic implications.结直肠癌中的 DNA 损伤反应和修复:缺陷、调控及治疗意义。
DNA Repair (Amst). 2018 Sep;69:34-52. doi: 10.1016/j.dnarep.2018.07.005. Epub 2018 Jul 17.
8
Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer.乳腺癌中的基础、氧化和烷化DNA损伤、DNA修复效能及诱变敏感性
Mutat Res. 2004 Oct 4;554(1-2):139-48. doi: 10.1016/j.mrfmmm.2004.04.001.
9
The DNA-damaging potential of tamoxifen in breast cancer and normal cells.他莫昔芬对乳腺癌细胞和正常细胞的DNA损伤潜力。
Arch Toxicol. 2007 Jul;81(7):519-27. doi: 10.1007/s00204-007-0188-3. Epub 2007 Feb 16.
10
Targeting DNA damage and repair: embracing the pharmacological era for successful cancer therapy.靶向 DNA 损伤与修复:拥抱癌症治疗的药理学时代。
Pharmacol Ther. 2012 Mar;133(3):334-50. doi: 10.1016/j.pharmthera.2011.11.010. Epub 2011 Dec 14.

引用本文的文献

1
Machine learning-derived peripheral blood transcriptomic biomarkers for early lung cancer diagnosis: Unveiling tumor-immune interaction mechanisms.基于机器学习的外周血转录组生物标志物用于早期肺癌诊断:揭示肿瘤-免疫相互作用机制
Biofactors. 2025 Jan-Feb;51(1):e2129. doi: 10.1002/biof.2129. Epub 2024 Oct 16.
2
Identification of a prognostic DNA repair gene signature in esophageal cancer.食管癌中一种预后性DNA修复基因特征的鉴定
J Gastrointest Oncol. 2024 Jun 30;15(3):829-840. doi: 10.21037/jgo-24-262. Epub 2024 Jun 27.
3
KHSRP has oncogenic functions and regulates the expression and alternative splicing of DNA repair genes in breast cancer MDA-MB-231 cells.
KHSRP 具有致癌功能,并调节乳腺癌 MDA-MB-231 细胞中 DNA 修复基因的表达和选择性剪接。
Sci Rep. 2024 Jun 26;14(1):14694. doi: 10.1038/s41598-024-64687-0.
4
DriverMP enables improved identification of cancer driver genes.DriverMP 可提高癌症驱动基因的识别能力。
Gigascience. 2022 Dec 28;12. doi: 10.1093/gigascience/giad106. Epub 2023 Dec 13.
5
Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.选择性抑制 ATM 依赖性双链断裂修复和检查点控制协同增强 ATR 抑制剂的疗效。
Mol Cancer Ther. 2023 Jul 5;22(7):859-872. doi: 10.1158/1535-7163.MCT-22-0685.
6
Risk stratification based on DNA damage-repair-related signature reflects the microenvironmental feature, metabolic status and therapeutic response of breast cancer.基于 DNA 损伤修复相关特征的风险分层反映了乳腺癌的微环境特征、代谢状态和治疗反应。
Front Immunol. 2023 Mar 24;14:1127982. doi: 10.3389/fimmu.2023.1127982. eCollection 2023.
7
Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers.PARP和ATR的联合抑制协同增强了HER2靶向抗体药物偶联物在HER2阳性癌症中的抗肿瘤活性。
Am J Cancer Res. 2023 Jan 15;13(1):161-175. eCollection 2023.
8
Construction of a DNA damage repair gene signature for predicting prognosis and immune response in breast cancer.构建用于预测乳腺癌预后和免疫反应的DNA损伤修复基因特征。
Front Oncol. 2023 Jan 11;12:1085632. doi: 10.3389/fonc.2022.1085632. eCollection 2022.
9
Novel GIRlncRNA Signature for Predicting the Clinical Outcome and Therapeutic Response in NSCLC.用于预测非小细胞肺癌临床结局和治疗反应的新型GIRlncRNA特征
Front Pharmacol. 2022 Aug 3;13:937531. doi: 10.3389/fphar.2022.937531. eCollection 2022.
10
Integrated Transcriptome and Metabolomic Analysis Reveal Anti-Angiogenic Properties of Disarib, a Novel Bcl2-Specific Inhibitor.整合转录组和代谢组学分析揭示新型 Bcl2 特异性抑制剂 Disarib 的抗血管生成特性。
Genes (Basel). 2022 Jul 6;13(7):1208. doi: 10.3390/genes13071208.